A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything

From Insulin Maker to Obesity Juggernaut

Ten years ago, Eli Lilly (NYSE:LLY | LLY Price Prediction) was a steady Indianapolis drugmaker known for insulin and a dependable dividend. In its 150th year, it now carries a market cap of roughly $1.117 trillion. The incretin era rewrote the company.

Tirzepatide drove most of that change. Lilly sells it as Mounjaro for type 2 diabetes and as Zepbound for obesity, which launched in late 2023. In Q2 2026 the pair generated $14.9 billion in revenue, and Lilly wrote roughly 6 out of 10 U.S. obesity prescriptions.

Lilly also kept building. The FDA approved its oral GLP-1 pill Foundayo in Q1 2026, and the company announced new plants from Indiana to Texas. Adding Mounjaro to China’s reimbursement list helped drive 172% international growth for the drug. FY2025 revenue reached $65.18 billion, up 44.7%.

Your $1,000 Grew to $18,637

1-Year Return

• Initial Investment: $1,000
• Current Value: $1,523.80
• Total Return: 52.38%
• S&P 500 (same period): $1,160.30 (16.03%)

5-Year Return

• Initial Investment: $1,000
• Current Value: $5,504.80
• Total Return: 450.48%
• Annualized Return: 40.65%
• S&P 500 (same period): $1,731 (73.1%)

10-Year Return

• Initial Investment: $1,000
• Current Value: $18,637.40
• Total Return: 1,763.74%
• Annualized Return: 33.98%
• S&P 500 (same period): $3,634 (263.4%)

These figures reflect share price growth only. Lilly lifted its quarterly dividend from $0.51 in 2016 to $1.73 in 2026, so dividends received over the decade would add to the total.

The 10-year result is roughly 5.1 times what the S&P 500 delivered, and Lilly beat the index at every horizon. Holding still took nerve. Shares fell about 22% between February 4 and April 30, 2026, then recovered to $1,251.61. Luck mattered too. A 2016 buyer had no way of knowing how large the obesity drug market would become.

Volume Growth Battles Price Cuts as Retatrutide Nears Filing

The bull case rests on retatrutide and Foundayo extending the franchise. Retatrutide has a complete Phase 3 package, and Lilly plans a U.S. submission in Q1 2027. Management also says obesity treatment remains at “mid-single digit” utilization. In Q2 2026, revenue rose 47.7% to $22.97 billion, and full-year guidance moved up to $85.0 billion to $87.0 billion.

The bear case centers on pricing erosion outrunning volume. Realized prices fell 13% in Q2 2026, and Mounjaro plus Zepbound still account for most of Lilly’s revenue. Acquired IPR&D charges of $3.03 per share also cut into Q2 earnings.

So far, volume has the edge. A 60% jump in volume is more than offsetting the price cuts, and an 85.8% gross margin leaves plenty of cushion. Investors researching the stock should weigh how they would handle another 20%-plus pullback.

Contact [email protected] for any questions or corrections.